42 related articles for article (PubMed ID: 38730456)
1. Single-cell exome sequencing identifies mutations in KCP, LOC440040, and LOC440563 as drivers in renal cell carcinoma stem cells.
Li C; Wu S; Yang Z; Zhang X; Zheng Q; Lin L; Niu Z; Li R; Cai Z; Li L
Cell Res; 2017 Apr; 27(4):590-593. PubMed ID: 27981968
[No Abstract] [Full Text] [Related]
2. Case report of multiple primary cancers and results of genetic testing to preliminarily explore their pathogenesis.
Hong Z; Tongsong Z; Cunhai C; Xiao L; Haiping S
SAGE Open Med Case Rep; 2024; 12():2050313X241252371. PubMed ID: 38803359
[TBL] [Abstract][Full Text] [Related]
3. A rare case of TFEB/6p21/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review.
Zhang R; Ding M; Zhu X; Li X; Hu Q; Tao L; Hu W; Zou H
Diagn Pathol; 2024 May; 19(1):66. PubMed ID: 38730456
[TBL] [Abstract][Full Text] [Related]
4. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Amin MB; Berney DM; Compérat EM; Gill AJ; Hartmann A; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Netto GJ
Eur Urol; 2022 Nov; 82(5):458-468. PubMed ID: 35853783
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy.
Gaikwad S; Agrawal MY; Kaushik I; Ramachandran S; Srivastava SK
Semin Cancer Biol; 2022 Nov; 86(Pt 3):137-150. PubMed ID: 35341913
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Akinboro O; Larkins E; Pai-Scherf LH; Mathieu LN; Ren Y; Cheng J; Fiero MH; Fu W; Bi Y; Kalavar S; Jafri S; Mishra-Kalyani PS; Fourie Zirkelbach J; Li H; Zhao H; He K; Helms WS; Chuk MK; Wang M; Bulatao I; Herz J; Osborn BL; Xu Y; Liu J; Gong Y; Sickafuse S; Cohen R; Donoghue M; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jun; 28(11):2221-2228. PubMed ID: 35101885
[TBL] [Abstract][Full Text] [Related]
7. The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer.
Nam H; Kundu A; Karki S; Brinkley GJ; Chandrashekar DS; Kirkman RL; Liu J; Liberti MV; Locasale JW; Mitchell T; Varambally S; Sudarshan S
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34609963
[TBL] [Abstract][Full Text] [Related]
8. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-independent function of lipidated LC3 essential for TFEB activation during the lysosomal damage responses.
Nakamura S; Akayama S; Yoshimori T
Autophagy; 2021 Feb; 17(2):581-583. PubMed ID: 33150842
[TBL] [Abstract][Full Text] [Related]
10. The role of TFEB in tumor cell autophagy: Diagnostic and therapeutic opportunities.
Bahrami A; Bianconi V; Pirro M; Orafai HM; Sahebkar A
Life Sci; 2020 Mar; 244():117341. PubMed ID: 31972208
[TBL] [Abstract][Full Text] [Related]
11. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.
Gupta S; Argani P; Jungbluth AA; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Sanchez A; Hakimi AA; Mcfarlane T; Salazar PA; Williamson SR; Skala SL; Mehra R; Hes O; Antonescu CR; Ladanyi M; Arcila ME; Reuter VE
Am J Surg Pathol; 2019 Nov; 43(11):1445-1461. PubMed ID: 31600176
[TBL] [Abstract][Full Text] [Related]
12. The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma.
Yang WH; Ding CC; Sun T; Rupprecht G; Lin CC; Hsu D; Chi JT
Cell Rep; 2019 Sep; 28(10):2501-2508.e4. PubMed ID: 31484063
[TBL] [Abstract][Full Text] [Related]
13. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
14. Cooperation among cancer cells: applying game theory to cancer.
Archetti M; Pienta KJ
Nat Rev Cancer; 2019 Feb; 19(2):110-117. PubMed ID: 30470829
[TBL] [Abstract][Full Text] [Related]
15. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer.
Peng D; Hu Z; Wei X; Ke X; Shen Y; Zeng X
IUBMB Life; 2019 Jan; 71(1):113-124. PubMed ID: 30281919
[TBL] [Abstract][Full Text] [Related]
16. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations.
Caliò A; Brunelli M; Segala D; Pedron S; Doglioni C; Argani P; Martignoni G
Mod Pathol; 2019 Feb; 32(2):258-268. PubMed ID: 30206412
[TBL] [Abstract][Full Text] [Related]
17. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
18. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.
Guarch R; Lawrie CH; Larrinaga G; Angulo JC; Pulido R; López JI
Ann Diagn Pathol; 2018 Jun; 34():27-30. PubMed ID: 29661723
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
